STING Agonist 8803 Reprograms the Immune Microenvironment and Increases Survival in Preclinical Models of Glioblastoma

Version
STING Agonist 8803 Reprograms the Immune Microenvironment and Increases Survival in Preclinical Models of Glioblastoma

CTSA https://pubmed.ncbi.nlm.nih.gov/38941297/ 2024-06-17T00:00:00Z The Journal of Clinical Investigation